Author Archive

NCfIH Marks RSV Awareness Month with Release of New “Fast Facts”

October marks the beginning of both the RSV viral season and RSV awareness month. The National Coalition for Infant Health is taking the opportunity to

Read More

Nordic Patient Groups Tackle Biosimilar Policy Issues

Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which

Read More

New IfPA Data Support Non-Medical Switching Concerns

Preliminary data from the Institute for Patient Access suggest what opponents of non-medical switching have long suspected: having medications switched for financial reasons could be

Read More

New Report: Biosimilar Cost Savings Won’t Reach Patients

Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer.

Read More

Are New Cancer Meds Worth Their Cost?

Innovative but costly anti-cancer drugs have spurred the development of several value assessments and cost frameworks, all designed to explore one question: Do the benefits

Read More

New Data: Illegal Drugs Drive Massachusetts’ Opioid Overdose Epidemic

New data show that street drugs, not prescription opioids, directly caused 85 percent of opioid overdose deaths in Massachusetts during 2013 and 2014. The state

Read More

The PCSK9 Inhibitor Conundrum

A guest blog by Seth Baum, M.D. Medicine is at a crossroads; cardiology in particular. I saw this fact magnified at the American Society for

Read More

CCTA Panel Explores Making Clinical Trials Conversation Standard of Care

What if discussing clinical trials opportunities were a standard part of patient care? This question spurred discussion among members of a diverse panel at a

Read More

Rx Pricing, Patents & Patient Access

A United Nations panel has a controversial idea for improving patient access to necessary medicines: curb intellectual property rights. The UN High Level Panel on

Read More

IfPA Urges ICER to Improve Value Framework

Along with other advocacy, education and health care organizations, the Institute for Patient Access wrote to the Institute for Clinical and Economic Review this week

Read More
Back to Top